VERU on Nasdaq

VERU INC.

We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and inflammatory diseases.5 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

-$22.7MNet income, fiscal 20253

Compare with Zhengye Biotechnology Holding Ltd, uniQure N.V. or KIORA PHARMACEUTICALS INC, or pick any stock.

  • TickerVERU on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersMiami, United States2
  • Incorporated inWI4
  • Business address2916 N. Miami Avenue, Suite 1000, Miami, Fl 331274
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI529900ER63TFLEIJV6312
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o C T CORPORATION SYSTEM, 301 S. BEDFORD ST. SUITE 1, 53703 Madison, United States2

See how the biggest companies compare on our leaderboards

We are a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic and inflammatory diseases. Our drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator (“SARM”), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass. This activity leads to improved body composition and physical function with expected clinically meaningful incremental weight reduction versus GLP-1 RA monotherapy. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease. On December 30, 2024, the Company sold its FDA-approved commercial product, the FC2 Female Condom® (Internal Co…5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

34.7%Gross margin6
-214.2%Operating margin3
-223.9%Net margin3
3.6%Revenue growth, 20246
-117.0%Return on equity3
-$21.8MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue20¢$11.0M
  • Research and development23¢$12.8M
  • Selling, general and admin57¢$31.2M

Out of $16.9M in revenue.63 The company lost money this year.

Financial statements

Revenue78910116$16.9M in 2024+6% since 2018
0$20.0M$40.0M$60.0M$80.0M2018: $15.9M$15.9M20182019: $31.8M$31.8M2019+100%2020: $42.6M$42.6M2020+34%2021: $61.3M$61.3M2021+44%2022: $39.4M$39.4M2022−36%2023: $16.3M$16.3M2023−59%2024: $16.9M$16.9M2024+4%
Gross profit78910116$5.9M in 2024−33% since 2018
0$20.0M$40.0M$60.0M2018: $8.8M$8.8M20182019: $21.7M$21.7M2019+147%2020: $30.8M$30.8M2020+42%2021: $47.9M$47.9M2021+56%2022: $30.6M$30.6M2022−36%2023: $7.6M$7.6M2023−75%2024: $5.9M$5.9M2024−23%
Operating income789101163-$36.2M in 2024+73% since 2018
-$100.0M-$50.0M0$50.0M2018: -$20.9M-$20.9M20182019: -$6.4M-$6.4M2019−69%2020: -$14.7M-$14.7M2020+129%2021: $13.0M$13.0M20212022: -$83.5M-$83.5M20222023: -$93.8M-$93.8M2023+12%2024: -$36.2M-$36.2M2024−61%
Net income789101163-$37.8M in 2024+58% since 2018
-$100.0M-$50.0M0$50.0M2018: -$23.9M-$23.9M20182019: -$12.0M-$12.0M2019−50%2020: -$19.0M-$19.0M2020+58%2021: $7.4M$7.4M20212022: -$84.0M-$84.0M20222023: -$93.2M-$93.2M2023+11%2024: -$37.8M-$37.8M2024−59%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-09-302024-09-30
Research and development$15.6M$12.8M
General and administrative$19.9M$24.6M
Total operating expenses$35.5M$37.4M
Gain on sale of ENTADFI assets$10.8M$1.2M
Operating loss-$24.8M-$36.2M
Gain on extinguishment of debt$8.6M$0
Change in fair value of equity securities-$323.8K-$176.1K
Other income, net$768.4K$1.1M
Total non-operating income$9.1M$909.1K
Net loss from continuing operations-$15.7M-$35.3M
Net loss from discontinued operations, net of taxes-$7.0M-$2.5M
Net loss-$22.7M-$37.8M
Net loss from continuing operations per basic and diluted common shares outstanding (in dollars per share)-$1-$3
Net loss from discontinued operations per basic and diluted common shares outstanding (in dollars per share)-$0-$0
Net loss per basic and diluted common shares outstanding (in dollars per share)-$1.55-$2.80
Basic and diluted weighted average common shares outstanding (in shares)14.6M shares13.5M shares

Compare VERU INC. with another company

Leadership

Who has led VERU INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. O. B. Parrish2006–2016
  2. Karen Louise King2014–2015
  3. Mitchell Shuster Steiner2016–2019
  4. Charles T. Todd Jr.2019

Chair

  1. O. B. Parrish2006–2012

President

  1. O. B. Parrish2009–2013
  2. Karen Louise King2014–2015
  3. Mitchell Shuster Steiner2016–now

Chief financial officer

  1. Donna Felch2006–2012
  2. Daniel Haines2016–2017

Chief operating officer

  1. O. B. Parrish2006–2009
  2. Daniel Haines2016
2010201520202025
Board members and other officers (33)

Former names

  • FEMALE HEALTH COJun 13, 1996 to Aug 1, 20174

Timeline

  1. Jan 3, 2019New chief executive Charles T. Todd Jr. becomes CEO15
  2. Nov 7, 2016New chief executive Mitchell Shuster Steiner becomes CEO16
  3. Jan 21, 2014New chief executive Karen Louise King becomes CEO17
  4. May 8, 2006New chief executive O. B. Parrish becomes CEO18

Filings

241 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 56 major events, 84 insider forms, 23 large holders, 56 other. The latest 20:

  1. Sep 8, 20268-K EDGAR
  2. Aug 17, 20264 PRIMARY DOCUMENT EDGAR
  3. Aug 10, 202610-Q EDGAR
  4. Aug 10, 20268-K EDGAR
  5. Jul 2, 20268-K EDGAR
  6. Jul 2, 2026424B5 EDGAR
  7. Jun 4, 20268-K EDGAR
  8. May 13, 2026S-8 EDGAR
  9. May 13, 202610-Q EDGAR
  10. May 13, 20268-K EDGAR
  11. May 6, 20264 PRIMARY DOCUMENT EDGAR
  12. May 6, 20264 PRIMARY DOCUMENT EDGAR
  13. May 6, 20264 PRIMARY DOCUMENT EDGAR
  14. May 6, 20264 PRIMARY DOCUMENT EDGAR
  15. May 6, 20264 PRIMARY DOCUMENT EDGAR
  16. May 6, 20264 PRIMARY DOCUMENT EDGAR
  17. May 6, 20264 PRIMARY DOCUMENT EDGAR
  18. May 6, 20264 PRIMARY DOCUMENT EDGAR
  19. Apr 15, 2026EFFECT EDGAR
  20. Apr 15, 2026EFFECT EDGAR

The 241 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

13 open-market trades by officers, directors and large owners since October 2021: 6 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 13, 2026BARNETTE K GARYChief Scientific OfficerBuy1,800$2.69$4.8KForm 4
Feb 19, 2025Rankowitz Michael LDirectorBuy54,721$0.58$31.7KForm 4
Feb 18, 2025Rankowitz Michael LDirectorBuy95,279$0.55$52.4KForm 4
May 24, 2024FISCH HARRYChief Corporate OfficerBuy4,000$1.25$5.0KForm 4
May 24, 2024BARNETTE K GARYChief Scientific OfficerBuy5,000$1.34$6.7KForm 4
May 24, 2024STEINER MITCHELL SHUSTERPresident and CEOSale63,379$1.23$78.0KForm 4
May 23, 2024STEINER MITCHELL SHUSTERPresident and CEOSale300$1.35$405Form 4
May 22, 2024STEINER MITCHELL SHUSTERPresident and CEOSale6,504$1.39$9.0KForm 4
May 17, 2024STEINER MITCHELL SHUSTERPresident and CEOSale28,066$1.32$37.0KForm 4
May 16, 2024STEINER MITCHELL SHUSTERPresident and CEOSale59,788$1.41$84.3KForm 4
May 15, 2024FISCH HARRYChief Corporate OfficerBuy6,711$1.49$10.0KForm 4
May 15, 2024STEINER MITCHELL SHUSTERPresident and CEOSale84,021$1.50$126.0KForm 4
Aug 15, 2022Eisenberger MarioDirectorSale100,000$20.04$2.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 59. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC698,439$2.2M0.0%+159,057
Alyeska Investment Group, L.P.238,556$746.7K0.0%−761,444
Oppenheimer & Co Inc210,843$659.9K0.0%+14,543
BlackRock, Inc.167,084$523.0K0.0%+52,915
Renaissance Technologies LLC164,450$514.7K0.0%+95,200
Geode Capital Management, LLC155,076$485.5K0.0%−29,546
Summit Financial, LLC141,865$444.0K0.0%−9,918
Jane Street Group, LLC127,853$400.2K0.0%+105,046
Raymond James Financial Inc84,969$266.0K0.0%+17,408
Vanguard Fiduciary Trust Co81,230$254.2K0.0%+577
Choreo, LLC74,813$234.2K0.0%−450
NewEdge Advisors, LLC70,439$220.5K0.0%+114
Citadel Advisors LLC61,977$194.0K0.0%+17,495
Blair William & Co/il58,000$181.5K0.0%+10,000
State Street Corp55,004$172.2K0.0%No change
Diametric Capital, LP50,192$157.1K0.0%New
Algert Global LLC42,144$131.9K0.0%New
ADAR1 Capital Management, LLC35,000$109.5K0.0%No change
Northern Trust Corp29,855$93.4K0.0%−3,733
Scientech Research LLC28,391$88.9K0.1%New
Integrated Wealth Concepts LLC23,165$72.5K0.0%+11,400
Marshall Wace, Llp20,300$63.5K0.0%New
Quantinno Capital Management LP20,000$62.6K0.0%No change
Osaic Holdings, Inc.16,253$50.9K0.0%−365
Susquehanna International Group, Llp12,597$39.4K0.0%−174

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63